Dare Bioscience Hit With Second Nasdaq Delisting Notice — Now Below $1 Minimum Bid Price
DARE sits 22% above its 52-week low of $0.69 on light trading volume (0.3× avg).
Summary
Dare Bioscience received a second Nasdaq delisting notice on September 28, 2026, this time for its stock trading below $1.00. The company has until March 29, 2027 to regain compliance and may pursue a reverse stock split.
Key Events · Legal and Risk Events · DARE
-
Second Nasdaq Delisting Notice
Nasdaq notified Dare Bioscience on September 28, 2026 that its stock closed below $1.00 for 30 consecutive business days, violating the Minimum Bid Price Requirement (Rule 5550(a)(2)).
-
Compliance Deadline Set
Dare has 180 calendar days, until March 29, 2027, to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.
-
Reverse Split Contingency
The company states it may effect a reverse stock split to cure the deficiency if it cannot regain compliance through market price appreciation.
-
Compounding Listing Risk
This minimum bid price deficiency is separate from the July 2026 stockholders' equity deficiency, meaning Dare now faces two distinct Nasdaq listing compliance issues.
Analysis · DARE · Life Sciences
A new Nasdaq deficiency notice landed on September 28, 2026, this time for failing the $1.00 minimum bid price rule — a separate listing standard from the stockholders' equity deficiency disclosed in July. The company has until March 29, 2027 to regain compliance, and it explicitly states it may pursue a reverse stock split to do so. With the stock trading at $0.84, the company faces a forced reverse split or delisting, compounding the going-concern and FDA concerns already disclosed in its Q2 10-Q.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 44.5% of the 299 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $0.69 to $3.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.